COMMUNIQUÉS West-GlobeNewswire

The Jackson Laboratory and Crown Bioscience Announce Global Pre-Clinical Research Agreement
20/06/2017
BAR HARBOR, Maine and SANTA CLARA, Calif., June 20, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience (CrownBio), a wholly owned subsidiary of Crown Bioscience International (TWSE: ticker 6554), and The Jackson Laboratory (JAX [...]
Holaira Announces Company Name Change to Nuvaira
20/06/2017
Company Adds Shane Gleason to Executive Team MINNEAPOLIS, June 20, 2017 (GLOBE NEWSWIRE) -- Holaira , a developer of medical devices to treat obstructive lung diseases, today announced that it has changed its name to [...]
The Jackson Laboratory et Crown Bioscience annoncent un accord mondial de recherche préclinique
20/06/2017
BAR HARBOUR (Maine) et SANTA CLARA (Californie), le 20 juin 2017 (GLOBE NEWSWIRE) - Crown Bioscience (CrownBio), filiale en propriété exclusive de Crown Bioscience International (TWSE : symbole boursier 6554) et The [...]
Holaira annonce le changement de dénomination de la société pour devenir Nuvaira
20/06/2017
Shane Gleason joint l'équipe de direction de la société MINNEAPOLIS, le 20 juin 2017 (GLOBE NEWSWIRE) - Holaira , développeur de dispositifs médicaux destinés à traiter les maladies pulmonaires obstructives, a annoncé [...]
Helsinn Group Announces Upcoming Presentation of Phase III data in NEPA (netupitant/palonestron) at MASCC/ISOO Congress in Washington DC
20/06/2017
Helsinn Group Announces Upcoming Presentation of Phase III data in NEPA (netupitant/palonestron) at MASCC/ISOO Congress in Washington DC Data demonstrates the non-inferiority of NEPA versus an aprepitant (APR)/ [...]
Nokia launches portfolio of digital health products designed to inspire people to take control of their health
20/06/2017
Nokia expands in digital health; company announces largest line of connected consumer health products New products include Nokia Body BMI Wi-Fi connected scale, Nokia BPM+ soft-cuff blood pressure monitor, new Nokia [...]
Galapagos' R&D Update 2017: rapidly advancing our product candidates
20/06/2017
Filgotinib Darwin 3: improved activity, consistent safety parameters for filgotinib Ph2 studies initiated in 6 new indications Cystic fibrosis Three different triple combos in development Successful completion of Ph1 [...]
Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval
20/06/2017
RTH258 achieved the primary efficacy endpoint of non-inferiority to aflibercept in mean change in BCVA from baseline to week 48[1],[2] in two head-to-head pivotal Phase III studies[3],[4] 57% and 52% of patients [...]
Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden
20/06/2017
Urgent need to improve management of chronic urticaria (CU) - a disease that causes itchy, persistent hives and swelling which last more than 6 weeks or recur over months or years - highlighted by study of over 3,700 [...]
argenx receives second preclinical milestone payment in collaboration with LEO Pharma
20/06/2017
June 20, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]
NEOVACS ANNONCE LA FIN DU RECRUTEMENT DES PATIENTS POUR SON ETUDE CLINIQUE DE PHASE IIB DANS LE TRAITEMENT DU LUPUS
20/06/2017
NEOVACS ANNONCE LA FIN DU RECRUTEMENT DES PATIENTS POUR SON ETUDE CLINIQUE DE PHASE IIB DANS LE TRAITEMENT DU LUPUS Perspective de publication des résultats cliniques au cours du deuxième trimestre 2018 Paris et Boston [...]
NEOVACS ANNOUNCES THE COMPLETION OF PATIENT ENROLLMENT IN PHASE IIB CLINICAL STUDY OF IFNalpha KINOID IN LUPUS
20/06/2017
NEOVACS ANNOUNCES THE COMPLETION OF PATIENT ENROLLMENT IN PHASE IIB CLINICAL STUDY OF IFNalpha KINOID IN LUPUS Company Expects the Availability of Results from the Study in Q2 2018 Paris and Boston, June 20, 2017 - 7:00 [...]
Takeda and TiGenix announce that Swissmedic has accepted for review the file on Cx601 for the treatment of complex perianal fistulas in Crohn's disease patients
20/06/2017
PRESS RELEASE Takeda and TiGenix announce that Swissmedic has accepted for review the file on Cx601 for the treatment of complex perianal fistulas in Crohn's disease patients Pfäffikon, SZ, June 20, 2017, and Leuven, [...]
Takeda et TiGenix annoncent que Swissmedic a accepté la demande d'évaluation relative au Cx106 pour le traitement des fistules périanales complexes chez les patients atteints de la maladie de Crohn.
20/06/2017
COMMUNIQUÉ DE PRESSE Takeda et TiGenix annoncent que Swissmedic a accepté la demande d'évaluation relative au Cx106 pour le traitement des fistules périanales complexes chez les patients atteints de la maladie de Crohn [...]
Immunicum Announces Publication in Journal for ImmunoTherapy of Cancer of Results Overview from Ilixadencel's First Clinical Study in Metastatic Renal Cell Carcinoma
20/06/2017
Press Release 20 June 2017 Immunicum Announces Publication in Journal for ImmunoTherapy of Cancer of Results Overview from Ilixadencel's First Clinical Study in Metastatic Renal Cell Carcinoma Immunicum AB (publ; First [...]
Sanofi : Disclosure of trading in own shares
19/06/2017
Reporting EN This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]
Sanofi : Déclaration des transactions sur actions propres
19/06/2017
Reporting FR This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]
Ossur Hf : Transactions in relation to share buyback program
19/06/2017
Announcement from Össur hf. No. 45/2017 Reykjavík, 19 June 2017 On 1 December 2016, Össur hf. initiated a new share buy-back program, see Company announcement no. 96/2016. The purpose of the share buyback program is to [...]
Helén Tuvesson new CEO of Active Biotech AB from July 1, 2017
19/06/2017
PRESS RELEASE Lund - Active Biotech AB (Nasdaq Stockholm: ACTI) today announces that the Board has appointed the company's current CSO Helén Tuvesson as new CEO of Active Biotech AB. Helén Tuvesson will take up the [...]

Pages